Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)18.19bn
- Net income in MXN1.72bn
- Incorporated1996
- Employees1.71k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | 1.38bn | 504.92m | 16.71bn | 97.00 | 34.07 | 4.17 | 31.34 | 12.09 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Jeena Sikho Lifecare Ltd | -18.95bn | -18.95bn | 16.91bn | 3.76k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.29 | -- | 40.74 | -- | 92.07 | -- | 16.78 | -- | -- | -- | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Shanghai OPM Biosciences Co Ltd | 878.98m | 107.70m | 17.05bn | 328.00 | 140.33 | 2.84 | -- | 19.40 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Tchaikapharma High Quality Medicines AD | 627.12m | 69.71m | 17.35bn | 209.00 | 260.05 | 15.11 | 171.60 | 27.67 | 0.0359 | 0.0359 | 0.3225 | 0.6169 | 0.4682 | 2.46 | 0.9284 | 149,417.00 | 5.21 | 2.11 | 5.87 | 2.44 | 35.06 | 29.47 | 11.12 | 5.56 | 4.90 | 174.93 | 0.0926 | -- | 9.72 | 8.94 | 32.14 | 11.82 | -- | -- |
| Genomma Lab Internacional SAB de CV | 18.19bn | 1.72bn | 17.40bn | 1.71k | 10.20 | 1.54 | 8.21 | 0.9566 | 1.71 | 1.15 | 18.06 | 11.27 | 0.7721 | 3.09 | 3.71 | 11,333,190.00 | 7.28 | 6.85 | 10.26 | 10.26 | 63.30 | 61.94 | 9.43 | 8.93 | 1.54 | 3.88 | 0.4025 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
| Sanofi India Ltd | 3.66bn | 675.17m | 17.50bn | 991.00 | 25.92 | -- | 23.46 | 4.78 | 154.71 | 154.71 | 839.09 | -- | -- | -- | -- | 19,500,500.00 | -- | 22.31 | -- | 31.44 | 51.42 | 54.10 | 18.44 | 21.53 | -- | 321.27 | -- | 132.73 | 0.8567 | -8.10 | -13.96 | -5.41 | -13.65 | 1.99 |
| Cronos Group Inc | 2.28bn | 621.11m | 17.51bn | 626.00 | 29.58 | 0.9469 | 19.67 | 7.69 | 0.124 | 0.124 | 0.4667 | 3.87 | 0.112 | 1.57 | 5.56 | -- | 3.51 | -8.99 | 3.81 | -9.77 | 43.35 | 2.22 | 31.36 | -159.15 | 21.28 | -- | 0.00 | -- | 34.82 | 37.71 | 158.81 | -48.79 | -19.52 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 1.77bn | -156.09m | 17.58bn | 925.00 | -- | 3.96 | -- | 9.92 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Shanghai Haixin Group Co Ltd | 1.96bn | 389.16m | 17.63bn | 715.00 | 64.45 | 2.16 | -- | 8.98 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
| Sanofi Consumer Healthcare India Ltd | 1.55bn | 412.91m | 17.82bn | 583.00 | 43.16 | -- | 41.39 | 11.52 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| China Shineway Pharmaceutical Group Ltd | 8.33bn | 2.06bn | 17.83bn | 2.87k | 7.89 | 0.9164 | 10.39 | 2.14 | 1.24 | 1.24 | 5.01 | 10.68 | 0.3299 | 1.15 | 3.81 | 1,174,909.00 | 8.17 | 8.29 | 10.75 | 10.38 | 73.36 | 74.83 | 24.77 | 18.67 | 3.39 | -- | 0.0419 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
Data as of Feb 19 2026. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
25.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 39.21m | 3.92% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 33.94m | 3.39% |
| Invesco Asset Management Ltd.as of 30 Jan 2026 | 33.36m | 3.34% |
| Skagen ASas of 30 Nov 2025 | 30.67m | 3.07% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 27.92m | 2.79% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 23.38m | 2.34% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 20.14m | 2.01% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 05 Feb 2026 | 19.29m | 1.93% |
| North of South Capital LLPas of 30 Jan 2026 | 15.57m | 1.56% |
| LarrainVial Asset Management AGF SAas of 31 Dec 2024 | 15.37m | 1.54% |
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
